OrbiMed’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

OrbiMed’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,029,300	Closed	-$47M	–	140
2023 Q1	$47M	Hold	2,029,300	–	–	0.92%	37
2022 Q4	$53.2M	Hold	2,029,300	–	–	1.02%	36
2022 Q3	$39.9K	Buy	2,029,300 +133,000	+7%	+$2.67M	0.74%	51
2022 Q2	$33.2K	Buy	1,896,300 +478,000	+34%	+$7.5M	0.6%	52
2022 Q1	$23.2M	Hold	1,418,300	–	–	0.38%	62
2021 Q4	$23.1M	Sell	1,418,300 -2,337	-0.2%	-$33.3K	0.3%	80
2021 Q3	$18.1M	Buy	1,420,637 +86,836	+7%	+$1.14M	0.2%	102
2021 Q2	$18.8M	Buy	1,333,801 +83,800	+7%	+$1.34M	0.19%	101
2021 Q1	$19.4M	Hold	1,250,001	–	–	0.18%	100
2020 Q4	$19.8M	Buy	+1,250,001	New	+$18.9M	0.17%	102
2016 Q1	–	Sell	-12,000	Closed	-$1.69M	–	146
2015 Q4	$1.69M	Sell	12,000 -201,104	-94%	-$27.3M	0.02%	118
2015 Q3	$20.6M	Hold	213,104	–	–	0.21%	70
2015 Q2	$32.3M	Buy	+213,104	New	+$35.2M	0.27%	69

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed's KDNY Position: Q2 2023 in Review

OrbiMed sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 2,029,300 shares — an estimated $47M sold.

OrbiMed first reported a position in KDNY in Q2 2015 and held it in 13 quarters. The position peaked at $53.2M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

OrbiMed reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
OrbiMed sold 2,029,300 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $47M.
OrbiMed first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 13 quarters.
OrbiMed's Chinook Therapeutics, Inc. Common Stock position peaked at $53.2M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.